Biotechnology

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

With its new HAE drug EKTERLY® smashing revenue forecasts, KalVista heads to key conferences where investors will scrutinize its path to profitability.

A novel nasal spray for progressive MS shows it can calm brain inflammation and boost neuroprotection, offering new hope for a difficult-to-treat disease.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.

With $400M in 2025 sales, Immunocore now leverages its KIMMTRAK success to fund a high-stakes pivot into broader cancers, HIV, and autoimmune disease.

With the appointment of TechTarget co-founder Don Hawk, Life Science Connect is set to import a proven B2B intent data playbook into the life sciences.

With sales rising and key FDA milestones met, Australian biotech Immuron resets its strategy, seeking partners to fund its promising infectious disease pipeline.

New research reveals how stomach cancer cells hijack healthy tissue to build supportive 'nests' in distant organs, opening a new front in the war on metastasis.

New FDA-cleared Persona PLUS technology promises to increase plasma yields per donor, tackling the growing global demand for life-saving therapies.

Promising trial data for onvansertib offers new hope for colorectal cancer patients, yet leadership changes and financial hurdles cloud the path forward.

The biotech firm secures major funding to push its promising head and neck cancer drug, ficerafusp alfa, toward regulatory approval and commercial launch.

A new Ontario program is giving breast cancer patients access to a life-changing drug a year sooner, setting a potential new standard for Canada.

A newly identified blood biomarker for the drug masitinib could revolutionize how doctors treat ALS, progressive MS, and Alzheimer's disease.

A planned reverse merger for promising vaccine developer SVF Vaccines has collapsed after Nasdaq rejected the deal, leaving its lead investor scrambling.

The tech firm announced progress on a major health contract, but with its stock near all-time lows, can this deal deliver a much-needed turnaround?

Dupixent's landmark FDA approval offers a new, surgery-sparing option for a debilitating sinus disease, but questions of access and cost remain.

Kenai Therapeutics hires a Novartis M&A veteran as CBO, signaling an aggressive strategy to advance its groundbreaking iPSC cell therapy for Parkinson's disease.